Literature DB >> 29408605

Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.

Kristy Truong1, Iram Ahmad1, J Jason Clark1, Alison Seline1, Tyler Bertroche1, Brian Mostaert1, Douglas J Van Daele1, Marlan R Hansen2.   

Abstract

Merlin is the protein product of the NF2 tumor suppressor gene. Germline NF2 mutation leads to neurofibromatosis type 2 (NF2), characterized by multiple intracranial and spinal schwannomas. Patients with NF2 also frequently develop peripheral neuropathies. While the role of merlin in SC neoplasia is well established, its role in SC homeostasis is less defined. Here we explore the role of merlin in SC responses to nerve injury and their ability to support axon regeneration. We performed sciatic nerve crush in wild-type (WT) and in P0SchΔ39-121 transgenic mice that express a dominant negative Nf2 isoform in SCs. Recovery of nerve function was assessed by measuring mean contact paw area on a pressure pad 7, 21, 60, and 90 days following nerve injury and by nerve conduction assays at 90 days following injury. After 90 days, the nerves were harvested and axon regeneration was quantified stereologically. Myelin ultrastructure was analyzed by electron microscopy. Functional studies showed delayed nerve regeneration in Nf2 mutant mice compared to the WT mice. Delayed neural recovery correlated with a reduced density of regenerated axons and increased endoneurial space in mutants compared to WT mice. Nevertheless, functional and nerve conduction measures ultimately recovered to similar levels in WT and Nf2 mutant mice, while there was a small (∼17%) reduction in the percent of regenerated axons in the Nf2 mutant mice. The data suggest that merlin function in SCs regulates neural ultrastructure and facilitates neural regeneration, in addition to its role in SC neoplasia.
Copyright © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Schwann cells; axon-Schwann cell interaction; merlin; nerve regeneration; sciatic nerve

Mesh:

Substances:

Year:  2018        PMID: 29408605      PMCID: PMC5841622          DOI: 10.1016/j.neuroscience.2018.01.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  39 in total

1.  Type II neurofibromatosis presenting as quadriceps atrophy.

Authors:  L Grazzi; L Chiapparini; E A Parati; S Giombini; D D'Amico; M Leone; G Bussone
Journal:  Ital J Neurol Sci       Date:  1998-04

2.  Cdc42 regulates Schwann cell radial sorting and myelin sheath folding through NF2/merlin-dependent and independent signaling.

Authors:  Li Guo; Chandra Moon; Yi Zheng; Nancy Ratner
Journal:  Glia       Date:  2013-09-06       Impact factor: 7.452

3.  Reduced expression of schwannomin/merlin in human sporadic meningiomas.

Authors:  J H Lee; V Sundaram; D J Stein; S E Kinney; D W Stacey; M Golubić
Journal:  Neurosurgery       Date:  1997-03       Impact factor: 4.654

4.  Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.

Authors:  Iram Ahmad; Augusta Fernando; Richard Gurgel; J Jason Clark; Linjing Xu; Marlan R Hansen
Journal:  Neurobiol Dis       Date:  2015-06-06       Impact factor: 5.996

5.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

6.  Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells.

Authors:  S S Scherer; D H Gutmann
Journal:  J Neurosci Res       Date:  1996-12-01       Impact factor: 4.164

7.  Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy.

Authors:  Alexander Schulz; Stephan L Baader; Michiko Niwa-Kawakita; Marie Juliane Jung; Reinhard Bauer; Cynthia Garcia; Ansgar Zoch; Stephan Schacke; Christian Hagel; Victor-Felix Mautner; C Oliver Hanemann; Xin-Peng Dun; David B Parkinson; Joachim Weis; J Michael Schröder; David H Gutmann; Marco Giovannini; Helen Morrison
Journal:  Nat Neurosci       Date:  2013-03-03       Impact factor: 24.884

8.  Association of Caspr/paranodin with tumour suppressor schwannomin/merlin and beta1 integrin in the central nervous system.

Authors:  Natalia Denisenko-Nehrbass; Laurence Goutebroze; Thierry Galvez; Carine Bonnon; Bruno Stankoff; Pascal Ezan; Marco Giovannini; Catherine Faivre-Sarrailh; Jean-Antoine Girault
Journal:  J Neurochem       Date:  2003-01       Impact factor: 5.372

9.  Schwannomas provide insight into the role of p75(NTR) and merlin in Schwann cells following nerve injury and during regeneration.

Authors:  Elise Cheng; Marlan R Hansen
Journal:  Neural Regen Res       Date:  2016-01       Impact factor: 5.135

10.  Neuronal merlin influences ERBB2 receptor expression on Schwann cells through neuregulin 1 type III signalling.

Authors:  Alexander Schulz; Anna Kyselyova; Stephan L Baader; Marie Juliane Jung; Ansgar Zoch; Victor-Felix Mautner; Christian Hagel; Helen Morrison
Journal:  Brain       Date:  2013-12-05       Impact factor: 13.501

View more
  3 in total

1.  Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.

Authors:  Jennifer Kersigo; Lintao Gu; Linjing Xu; Ning Pan; Sarath Vijayakuma; Timothy Jones; Seiji B Shibata; Bernd Fritzsch; Marlan R Hansen
Journal:  Laryngoscope       Date:  2020-05-21       Impact factor: 3.325

Review 2.  Pathomechanisms in schwannoma development and progression.

Authors:  Dario-Lucas Helbing; Alexander Schulz; Helen Morrison
Journal:  Oncogene       Date:  2020-07-02       Impact factor: 9.867

Review 3.  An update on the CNS manifestations of neurofibromatosis type 2.

Authors:  Shannon Coy; Rumana Rashid; Anat Stemmer-Rachamimov; Sandro Santagata
Journal:  Acta Neuropathol       Date:  2019-06-04       Impact factor: 17.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.